Citations

Clear

9383 citation(s) found for "Thomas, PS".

E-164 Safety profile of surgical embolectomy in acute ischemic stroke patients: a systematic review and meta-analysis
Pakkam, Madona , Bilgin, Cem , Kadirvel, R, Kallmes, D, Orscelik, Atakan , Musmar, Basel , Senol, Y, Ghozy, Sherief , Kadirvel, Ramanathan , Kallmes, David F.

Mayo Clinic

SNIS 21st annual meeting electronic poster abstracts | July 22, 2024 | Volume: No volume available | Issue: No issue available | Pages: A183.2-A184

10.1136/jnis-2024-snis.269 Get It

Acute kidney injury in severe alcohol-associated hepatitis treated with anakinra plus zinc or prednisone
Patidar, Kavish R. , Tu, Wanzhu , Cotter, Thomas G. , Asgharpour, Amon , Jan, Muhammad Y. , Tang, Qing , Taiwo, Moyinoluwa, Nagesh, Prashanth Thevkar , Kamath, Patrick S. , Chalasani, Naga , Nagy, Laura E. , Shah, Vijay H. , Investigators, for The AlcHepNet, Vargas, Hugo E. , Duarte‐Rojo, Andrés , Simonetto, Douglas A , Thevkar Nagesh, Prashanth , Dasarathy, Srinivasan , Kamath, Patrick S , Szabo, Gyongyi , Mitchell, Mack , Mehal, Wajahat Z , Gawrieh, Samer , Sanyal, A J , Cotter, T G , Vargas, Hugo E , Duarte-Rojo, Andres , Patidar, Kavish R , Simonetto, Douglas A. , Yu, Yunpeng , Li, Yang , McClain, Craig J. , Bataller, Ramon A , Gawrieh, Samer , Sanyal, Arun J. , Investigators, for The AlcHepNet

Mayo Clinic

Hepatology | July 19, 2024 | Volume: 81 | Issue: 4 | Pages: 1256-1268

10.1097/hep.0000000000001019 | PMID 39028887 Get It

Background and Aims: In a recent trial, patients with severe alcohol-associated hepatitis treated with anakinra plus zinc (A+Z) had lower survival and higher acute kidney injury (AKI) rates versus prednisone (PRED). We characterize the clinical factors and potential mechanisms associated with AKI development in that trial. Approach and Results: Data from 147 participants in a multicenter randomized clinical trial (74 A+Z, 73 PRED) were analyzed. AKI, AKI phenotypes, and kidney injury biomarkers were compared between participants who did/did not develop AKI in the 2 treatment arms. Multivariable competing risk analyses were performed to identify baseline risk factors for incident AKI, with death treated as a competing event. Risk factors considered were age, sex, mean arterial pressure, white blood cell count, albumin, MELD, ascites, HE, and treatment arm. At baseline, no participants had AKI; 33% (n=49) developed AKI during follow-up. AKI incidence was higher in A+Z than in PRED (45% [n=33] versus 22% [n=16], p=0.001). AKI phenotypes were similar between the 2 treatment arms (p=0.361), but peak AKI severity was greater in A+Z than PRED (stage 3 n=21 [63.6%] vs. n=8 [50.0%], p=0.035). At baseline, urine-neutrophil-gelatinase–associated lipocalin levels were similar between participants who developed AKI in both treatment arms (p=0.319). However, day 7 and 14 urine-neutrophil-gelatinase–associated lipocalin levels were significantly elevated in participants treated with A+Z who developed AKI versus participants treated with PRED who developed AKI (p=0.002 and 0.032, respectively). On multivariable competing risk analysis, only A+Z was independently associated with incident AKI (subdistribution hazard ratio 2.35, p=0.005). Conclusions: AKI occurred more frequently and was more severe in participants treated with A+Z. A+Z–treated participants with AKI had higher urine-neutrophil-gelatinase–associated lipocalin, suggesting that A+Z maybe nephrotoxic in patients with severe alcohol-associated hepatitis.
Association Between Surgeon Sex and Days Alive at Home Following Surgery: A Population-Based Cohort Study
Heybati, Kiyan , Satkunasivam, Raj , Aminoltejari, Khatereh, Thomas, Hannah S. , Salles, Arghavan , Coburn, Natalie, Wright, Frances C. , Conn, Lesley Gotlib , Riveros, Carlos , McCartney, Colin J. L. , Armstrong, Kathleen , Bass, Barbara L. , Detsky, Allan S. , Coburn, Natalie, Luckenbaugh, Amy N. , Ranganathan, Sanjana , Jerath, Angela , Wallis, Christopher J D

Mayo Clinic

Annals of Surgery Open | July 19, 2024 | Volume: 5 | Issue: 3 | Pages: e477

10.1097/as9.0000000000000477 | PMID 39310349 Get It

Objective: The objective of this study was to measure potential associations between surgeon sex and number of days alive and at home (DAH). Background: Patients treated by female surgeons appear to have lower rates of mortality, complications, readmissions, and healthcare costs when compared with male surgeons. DAH is a validated measure, shown to better capture the patient experience of postoperative recovery. Methods: We conducted a retrospective study of adults (≥18 years of age) undergoing common surgeries between January 01, 2007 and December 31, 2019 in Ontario, Canada. The outcome measures were the number of DAH within 30-, 90-, and 365-days. The data was summarized using descriptive statistics and adjusted using multivariable generalized estimating equations. Results: During the study period, 1,165,711 individuals were included, of which 61.9% (N = 721,575) were female. Those managed by a female surgeon experienced a higher mean number of DAH when compared with male surgeons at 365 days (351.7 vs. 342.1 days; P < 0.001) and at each earlier time point. This remained consistent following adjustment for covariates, with patients of female surgeons experiencing a higher number of DAH at all time points, including at 365 days (343.2 [339.5–347.1] vs. 339.4 [335.9–343.0] days). Multivariable regression modeling revealed that patients of male surgeons had a significantly lower number of DAH versus female surgeons. Conclusions: Patients of female surgeons experienced a higher number of DAH when compared with those treated by male surgeons at all time points. More time spent at home after surgery may in turn lower costs of care, resource utilization, and potentially improve quality of life. Further studies are needed to examine these findings across other care contexts.
Mechanistic insights from the atomic-level quaternary structure of short-lived GPCR oligomers in live cells
Stoneman, Michael R. , Yokoi, Koki, Killeen, Thomas D. , Adhikari, Dhruba P. , Rahman, Sadia , Harikumar, Kaleeckal G. , Miller, Laurence J. , Harikumar, Kaleeckal G , Miller, Laurence J , Raicu, Valerică , Killeen, Thomas D. , Biener, Gabriel , Bista, Sanam, Rahman, Sadia, Popa, Ionel

Mayo Clinic

No container title available | July 19, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4683780/v1 | PMID 39070646 Get It

Abstract The functional significance of the interactions between proteins in living cells to form short-lived quaternary structures cannot be overemphasized. Yet, quaternary structure information is not captured by current methods, neither can those methods determine structure within living cells. The dynamic versatility, abundance, and functional diversity of G protein-coupled receptors (GPCRs) pose myriad challenges to existing technologies but also present these proteins as the ideal testbed for new technologies to investigate the complex inter-regulation of receptor-ligand, receptor-receptor, and receptor-downstream effector interfaces in living cells. Here, we present development and use of a novel method capable of overcoming existing challenges by combining distributions (or spectrograms) of FRET efficiencies from populations of fluorescently tagged proteins associating into oligomeric complexes in live cells with diffusion-like trajectories of FRET donors and acceptors obtained from molecular dynamics (MD) simulations. Our approach provides an atom-level picture of the binding interfaces within oligomers of the human secretin receptor (hSecR) in live cells and allows for extraction of mechanistic insights into the function of GPCRs oligomerization. This FRET-MD spectrometry approach is a robust platform for investigating protein-protein binding mechanisms and opens a new avenue for investigating stable as well as fleeting quaternary structures of any membrane proteins in living cells.
Transformation of marginal zone lymphoma to Hodgkin lymphoma
Moalem, Kamilia , Alderuccio, Juan Pablo , Habermann, Thomas, Link, Brian K. , Cerhan, James R. , Florindez, Jorge A. , Lossos, Izidore S. , Link, Brian K , Cerhan, James R , Lossos, Izidore S , Bommier, Côme

Mayo Clinic

Blood Advances | July 18, 2024 | Volume: 8 | Issue: 17 | Pages: 4559-4562

10.1182/bloodadvances.2024013434 | PMID 39024508 Get It

Analyzing Google Search Trends for Migraine Surgery and Nurtec in Response to Public Announcements
Fijany, Arman , Holan, Cole , Mubang, Ronnie, Montorfano, Lisandro , Olsson, Sofia E., Troia, Thomas, Bakian, Arash, Kassis, Salam Al, Tran, Bill , Tran, Bill V, Bishay, Anthony E.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | July 18, 2024 | Volume: 12 | Issue: 7 | Pages: e5996

10.1097/gox.0000000000005996 | PMID 39027895 Get It

Background: Nurtec, a versatile migraine medication, has gained popularity. However, the awareness of migraine surgery remains uncertain. Methods: Following a descriptive approach, this cross-sectional study used Google Trends data as of December 1, 2023, to analyze internet search patterns. Approval from Vanderbilt University’s institutional review board and adherence to Strengthening the Reporting of Observational Studies in Epidemiology guidelines were confirmed. Monthly relative search volume (RSV) data for “migraine surgery,” “Nurtec,” and “Rimegepant” were collected from January 1, 2004, to November 11, 2023, within the United States. Statistical analysis involved determining mean monthly RSV values and percentage changes for critical periods. Results: For “Nurtec,” a significant surge in RSV occurred from March 2020 to April 2020 (344%). Additional peaks were observed from June 2020 to July 2020 (66%), October 2020 to December 2020 (169%), May 2021 to June 2021 (33%), and May 2023 to June 2023 (14%). “Migraine surgery” exhibited a notable 400% increase in RSV, from March 2005 to May 2005. However, post-2006, RSV for “migraine surgery” consistently remained low without noticeable peaks. Conclusions: The analysis of RSV trends for “Nurtec” and “migraine surgery” from 2004 to 2023 reveals the impact of pivotal events and marketing strategies on public interest. The distinct peaks in “Nurtec” RSV align with Food & Drug Administration approvals and marketing campaigns, highlighting the medication’s accessibility. Conversely, the consistently low RSV for “migraine surgery” indicates limited awareness, emphasizing the need for enhanced promotion and education regarding surgical interventions.
Artificial intelligence in cardiovascular medicine: clinical applications
Lüscher, Thomas F. , Wenzl, Florian A. , D’Ascenzo, Fabrizio , Friedman, Paul A. , Antoniades, Charalambos , Luescher, T F

Mayo Clinic

European Heart Journal | July 17, 2024 | Volume: 45 | Issue: 40 | Pages: 4291-4304

10.1093/eurheartj/ehae465 | PMID 39158472 Get It

Abstract Clinical medicine requires the integration of various forms of patient data including demographics, symptom characteristics, electrocardiogram findings, laboratory values, biomarker levels, and imaging studies. Decision-making on the optimal management should be based on a high probability that the envisaged treatment is appropriate, provides benefit, and bears no or little potential harm. To that end, personalized risk–benefit considerations should guide the management of individual patients to achieve optimal results. These basic clinical tasks have become more and more challenging with the massively growing data now available; artificial intelligence and machine learning (AI/ML) can provide assistance for clinicians by obtaining and comprehensively preparing the history of patients, analysing face and voice and other clinical features, by integrating laboratory results, biomarkers, and imaging. Furthermore, AI/ML can provide a comprehensive risk assessment as a basis of optimal acute and chronic care. The clinical usefulness of AI/ML algorithms should be carefully assessed, validated with confirmation datasets before clinical use, and repeatedly re-evaluated as patient phenotypes change. This review provides an overview of the current data revolution that has changed and will continue to change the face of clinical medicine radically, if properly used, to the benefit of physicians and patients alike.
Predictors of Shock‐Reduction Programming and Its Impact on Implantable Cardioverter‐Defibrillator Therapies and Mortality: The CERTITUDE Registry
Beyer, Sebastian E. , Harrell, Camden , Mullane, Steven , Kutyifa, Valentina , Madhavan, Malini , Piccini, Jonathan P. , Upadhyay, Gaurav A. , Ip, James E. , Thomas, George , Liu, Christopher F. , Markowitz, Steven M. , Hayes, David L. , Lerman, Bruce B. , Cheung, Jim W , Cheung, Jim W. , Ip, James E.

Mayo Clinic

Journal of the American Heart Association | July 16, 2024 | Volume: 13 | Issue: 15 | Pages: No page available

10.1161/jaha.124.034500 | PMID 39011955 Get It

Background Shock‐reduction implantable cardioverter‐defibrillator programming (SRP) was associated with fewer therapies and improved survival in randomized controlled trials, but real‐world studies investigating SRP and associated outcomes are limited. Methods and Results The BIOTRONIK CERTITUDE registry was linked with the Medicare database. We included all patients with an implantable cardioverter‐defibrillator implanted between August 22, 2012 and September 30, 2021 in the United States. SRP was defined as programming to either a therapy rate cutoff ≥188 beats per minute or number of intervals to detection ≥30/40 for treatment. Among 6781 patients (mean 74±9 years; 27% women), 3393 (50%) had SRP. Older age, secondary prevention indication, and device implantation in the southern or western United States were associated with lower use of SRP. The cumulative incidence rate of implantable cardioverter‐defibrillator shocks was lower in the SRP group (5.1% shocks/patient year) compared with the non‐SRP group (7.2% shocks/patient year) (adjusted hazard ratio [HR], 0.83 [95% CI, 0.73–0.96]; P =0.005). Over a median follow‐up of 2.9 years, 739 deaths occurred in the SRP group and 822 deaths occurred in the non‐SRP group (adjusted HR, 0.97 [95% CI, 0.88–1.07]; P =0.569). SRP was associated with a lower all‐cause mortality among patients without ischemic heart disease compared with patients with ischemic heart disease (adjusted HR, 0.64 [95% CI, 0.48–0.87] versus adjusted HR, 1.02 [95% CI, 0.92–1.14]; P interaction =0.004). Conclusions Adoption of SRP is low in real‐world clinical practice. Age, clinical variables, and geographic factors are associated with use of SRP. In this study, SRP‐associated decrease in mortality was limited to patients without ischemic heart disease.